EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
TOP PICK

Pfizer Inc(PFE)

Jul 26, 2012
Base pharmaceutical company and have an AA rating. Chart shows a long upward trend. 3.75% dividend yield. Stop loss would be about $20.25. Target price of $31.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$23.49

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jul 25, 2012
(Market Call Minute.) A cash cow. Not a lot of growth here but a good yield.
Photo of Gordon ReidGordon ReidUnlock Rating
$23.33

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 20, 2012
Like many of the pharmaceutical companies, it has been a very slow grower. Structurally, with US legislature, it is difficult to fund drugs that are going to be successful that would generate a cash flow that will pay back the company before they go generic. Feels that this company gives you a good return but you are stuck with the low single digit growth. Better opportunities elsewhere.
Photo of Gordon ReidGordon ReidUnlock Rating
$22.67

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 20, 2012
Will be issuing an IPO on their pet medicine branch. This is the right step to downsize a little. A mammoth company that is having difficulty in getting all the pieces growing at the same time. Sold their nutrition business. Very low multiple and a nice yield but just not enough growth.
Photo of Don LatoDon Lato
No
Unlock Rating
$22.67

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 14, 2012
Model price $26.71, 21% upside. This market is looking for yield, which is 3.9% here. A perfect candidate if you want to hide in equities. Likes this space also.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.56

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jun 07, 2012
Generally, healthcare sector tends to be more defensive and stable. Nice yield of about 4%. Also expects there are some catalysts around the areas that this company might change or spin off, which could enhance shareholder value
Photo of Stan WongStan Wong
Owned
Unlock Rating
$21.94

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 18, 2012
We are in an environment where dividends count. This one gives a 3% plus yield. Any time the market goes through deflationary pockets, money rotates back to consumer staples, drugs, etc.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.57

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 20, 2012
Thinks there is lots of potential. Drug stocks are severely under owned. The patent cliff that people were looking for has already happened and they are looking forward to the new drugs that are coming along. The CEO decided PFE was too big so any big drug coming along would have to be mammoth to have an impact, so he is actively talking about selling off some parts of the business, such as the Animal health. Nice yield. Earnings start to grow after next year or two.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.80

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 13, 2012
Prefers Teva to Pfizer. PFE does not have the growth profile. 11 or 12 times earnings. Abbot labs are good too. If it falls 10% he would be all over it.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$22.01

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 13, 2012
(A Top Pick Feb 28/11. Up 13.97%.)
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.30

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 02, 2012
Dividend is safe, growth prospects of many of the large Parma are very muted.
Photo of Don LatoDon LatoUnlock Rating
$21.11

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 01, 2012
Pharma: The trend is really looking quite good. Hasn’t looked at Pfizer in a while. There was a time when it was 0% return for 10 years. Now, it is in the right sector and it is moving.
Photo of Mike S. Newton, CIM FCSIMike S. Newton, CIM FCSIUnlock Rating
$21.31

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jan 26, 2012
One of the defensive stocks that did very, very well last year. Starting to see it roll over a little bit. Technically speaking it still looks pretty sound with the 200 day moving upwards and the 50 day moving across the 200 day very recently. Dividend is about 4%. Doesn't look at this as a tremendous growing company but is in the mid to high single digit range.
Photo of Stan WongStan Wong
No
Unlock Rating
$21.63

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 09, 2012
(Market Call Minute.) Good dividend yield. Company is buying back a lot of stocks. Well-run in a very tough business.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$21.82

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 04, 2012
His model price is $26.88, which is a 22% positive differential. Yielding 4%. This happens to be one that has valuation and yield together, which is great. His target would be about $26.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.77

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 406 to 420 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica